Abstract
Diphtheria, a vaccine-preventable disease, has resurfaced in Nigeria, where many outbreaks
have been reported in recent years. The outbreaks have occurred across the country, including
in areas with high vaccination coverage. Corynebacterium diphtheriae, the causal agent, is a highly
contagious bacteria that can cause severe respiratory and systemic symptoms and can be fatal if not
treated. The reemergence of diphtheria in Nigeria is most likely due to a combination of factors, including
gaps in routine immunization regimens. The outbreak is further aggravated by multiple epidemics,
which have diverted resources and attention away from the emergency of other infectious
diseases. Furthermore, there is a lack of awareness of diphtheria in Nigeria. With a focus on the difficulties
in controlling the disease, methods of diagnosis, available treatments, and preventive
measures, this study provides a thorough analysis of diphtheria, covering its historical context, clinical
presentation, associated complications, and current outbreaks. It emphasizes how important vaccination,
early detection, and better access to healthcare are in reducing diphtheria outbreaks. The
study highlights the serious effects of diphtheria on public health, particularly in regions with scarce
resources and vaccine resistance, and offers a number of suggestions to overcome these challenges
and prevent further outbreaks.
Keywords:
Diphtheria, Corynebacterium diphtheriae, diphtheria toxin, bacterial infection, outbreak, reemergence.
[2]
Acosta AM, Tiwari TSP. Diphtheria 439-45.
[9]
Aregbeshola BS, Folayan MO. Nigeria’s financing of health care during the COVID-19 pandemic: Challenges and recommendations. World Med Heal Policy 2022; 6(14): 195-204.
[13]
America N, Bartlett J, Klebs E. acute infectious disease caused by the bacillus. 4-6.
[17]
Gower C, Lacy J, Oeser C, et al. Public health control and management of diphtheria in England: 2022 guidelines. UK Heal Secur Agency 2022; 1-54.
[23]
Lamichhane ARS. Diphtheria. In StatPearls Publishing 2022.
[30]
The OF, Updates S. Diphtheria situation report. 2023; 22(01): 1-4.
[36]
Delivorias A, Scholz N. Economic impact of epidemics and pandemics. Eur Paliamentary Res Serv 2020; (February): 1-10.
[37]
Jamison DT. Disease control priorities. In: improving health and reducing poverty. The Lancet 2018; 391: 11-4.
[41]
Olumade T, Adesanya A, Fred-Akintunwa IJ, Babalola D, Oguzie A. Infectious disease outbreak preparedness and response in Nigeria: History, limitations and recommendations for global health policy and practice. AIMS Public Health 2020; 7(4): 736-57.
[42]
Okafor C. Improving outcomes in the nigeria healthcare sector through public- private partnership. African Res Rev 2016; 10(4): 1.
[51]
Shallangwa MM, Musa SS, Iwenya HC, Manirambona E, Lucero-Prisno DE III, Tukur BM. Assessment of COVID-19 vaccine hesitancy among people living with HIV/AIDS: A single-centered study. PAMJ - One Heal 2023; p. 10.
[52]
Olu-Abiodun O, Abiodun O, Okafor N. COVID-19 vaccination in Nigeria: A rapid review of vaccine acceptance rate and the associated factors. In: Elelu N, Ed. PLoS One 2022; 17: p. (5)e0267691.
[58]
Lamichhane ARS. Diphtheria. In: StatPearls 2022.
[60]
Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus,
diphtheria, and pertussis among adults: use of tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis vaccine recommendations of
the Advisory Committee on Immunization Practices (ACIP) and recommendation
of ACIP, supported b. MMWR Recomm reports Morb
Mortal Wkly report Recomm reports 2006; 55(17): 1-37.
[62]
Kruk ME, Gage AD, Arsenault C, et al. The Lancet Global Health
Commission High-quality health systems in the Sustainable Development
Goals era : Time for a revolution 2018; 6: 1196-252.
[66]
Olaleke O, Okesanya O, Abioye S, et al. The Forms, challenges and strength of the monkeypox surveillance system in Nigeria. Ann Heal Res 2022; 8(4): 269-76.